Pulmonology

First clinical scan using XENOVIEW conducted at Cincinnati Children’s Hospital Medical Center

Retrieved on: 
Thursday, May 11, 2023
Male, Radiation, Surgeon, AIM, Pulmonology, Research, Ventilation, MRI, Hospital, Magnetic resonance imaging, Patient, Cystic fibrosis, Lahey Hospital & Medical Center, Ageing, Cincinnati, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Disease, Medical imaging

Durham, N.C. , May 11, 2023 (GLOBE NEWSWIRE) -- Polarean Imaging plc (AIM:POLX), the medical imaging company, announces that the first clinical scan utilising its XENOVIEW (xenon Xe 129 hyperpolarized) technology in the United States has taken place at Cincinnati Children’s Hospital Medical Center (“Cincinnati Children’s”).

Key Points: 
  • Durham, N.C. , May 11, 2023 (GLOBE NEWSWIRE) -- Polarean Imaging plc (AIM:POLX), the medical imaging company, announces that the first clinical scan utilising its XENOVIEW (xenon Xe 129 hyperpolarized) technology in the United States has taken place at Cincinnati Children’s Hospital Medical Center (“Cincinnati Children’s”).
  • The first patient to receive a clinical scan using XENOVIEW is a 19-year-old male with cystic fibrosis.
  • Cincinnati Children’s has several other patients it believes are medically indicated for the lung imaging XENOVIEW provides and anticipates performing scans to monitor patients on a more regular basis.
  • Richard Hullihen, CEO of Polarean, said: “The first clinical scan in the United States is a significant milestone for Polarean and the XENOVIEW technology.

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of ARS Pharmaceuticals, Inc. (SPRY) Investigation

Retrieved on: 
Wednesday, May 10, 2023
Class Action Lawsuit, Professional Services, Legal, ARS, NDA, Translation, Pulmonology, Patient, Anaphylaxis, Adrenaline, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, News, Food, Safety, Pharmaceutical industry

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ARS Pharmaceuticals, Inc. (“ARS” or “the Company”) (NASDAQ: SPRY).

Key Points: 
  • Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ARS Pharmaceuticals, Inc. (“ARS” or “the Company”) (NASDAQ: SPRY).
  • Investors who purchased ARS securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: www.bgandg.com/spry .
  • If you are aware of any facts relating to this investigation or purchased ARS shares, you can assist this investigation by visiting the firm’s site: www.bgandg.com/spry .
  • You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

ARS Pharmaceuticals Announces Availability of Briefing Documents for FDA Advisory Committee Meeting on neffy® for the Treatment of Type I Allergic Reactions Including Anaphylaxis

Retrieved on: 
Tuesday, May 9, 2023
Allergy, ARS, NDA, Pharmacokinetics, Trial of the century, Pain, Pulmonology, Patient, Nature, Anaphylaxis, Adrenaline, Rhinitis, SAN, PDUFA, Entrepreneurship, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Caregiver, Pharmaceutical industry

neffy has the potential to be the first, non-injectable epinephrine nasal spray medicine for the treatment of patients with allergic reactions (type 1), including anaphylaxis.

Key Points: 
  • neffy has the potential to be the first, non-injectable epinephrine nasal spray medicine for the treatment of patients with allergic reactions (type 1), including anaphylaxis.
  • The advisory committee meeting is scheduled to begin at 9:00 AM ET on May 11, 2023.
  • Briefing materials, including FDA’s addendum to the documents, and webcast information for the meeting can be accessed at https://www.fda.gov/advisory-committees/advisory-committee-calendar/may-... .
  • The Company is not responsible for the content of, nor the statements made in, the briefing materials that were prepared by the FDA.

The Inner Circle Acknowledges, Jahaira L. Serrano, MD, FACCP, as a Pinnacle Life Achiever for her contributions to the medical field

Retrieved on: 
Wednesday, May 3, 2023
COPD, DOS, Asthma, Pneumonia, University, Emphysema, NBPS, Pharynx, Education, University of Puerto Rico School of Dental Medicine, Service, Physician, COVID-19, Chest infection, Diagram, Respiratory system, Multimedia, Mentorship, Mortality, Lung, Pulmonology, Inner circle, Nose, Suite, University of Puerto Rico School of Medicine, Patient, National Board of Medical Examiners, Internal medicine, American College of Chest Physicians, Histology, Chronic obstructive pulmonary disease, American College, Ministry of Health (New Zealand), Medical degree, Nursing, Incidence, Science, MD, Surgeon, Biology, Medicine

ARECIBO, Puerto Rico, May 3, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Jahaira L. Serrano, MD, FACCP, is acknowledged as a Pinnacle Life Achiever for her contributions to the medical field.

Key Points: 
  • ARECIBO, Puerto Rico, May 3, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Jahaira L. Serrano, MD, FACCP, is acknowledged as a Pinnacle Life Achiever for her contributions to the medical field.
  • Dr. Serrano began her educational pathway at the University of Puerto Rico in Cayey where she earned a Bachelor of Science in Biology.
  • She then attended the University of Puerto Rico School of Medicine in 2002 where she completed a Medical Degree in 2002.
  • According to Dr. Serrano, the NBPS provides continuing board certification for DOs and MDs who uphold medical education and patient care standards.

Polarean to be a featured company at 2023 ATS Respiratory Innovation Summit

Retrieved on: 
Wednesday, May 3, 2023
AIM, ATS, RIS, Xe, Research, Doctor of Philosophy, Pulmonology, Government, Annals of the American Thoracic Society, Health, Conference, Management, Pharmaceutical industry

Durham, N.C., May 03, 2023 (GLOBE NEWSWIRE) -- Polarean Imaging plc (AIM: POLX), the medical imaging technology company, has been selected as one of the featured companies as a poster presenter at the American Thoracic Society’s (“ATS”) 2023 Respiratory Innovation Summit (“RIS"), taking place 19-20 May in Washington D.C.

Key Points: 
  • Durham, N.C., May 03, 2023 (GLOBE NEWSWIRE) -- Polarean Imaging plc (AIM: POLX), the medical imaging technology company, has been selected as one of the featured companies as a poster presenter at the American Thoracic Society’s (“ATS”) 2023 Respiratory Innovation Summit (“RIS"), taking place 19-20 May in Washington D.C.
  • The Respiratory Innovation Summit unites innovators, investors, clinicians, and advocacy groups who work in the field of pulmonary medicine.
  • The meeting historically attracts more than 275 global leaders representing all facets of the respiratory industry, including start-ups, venture capital, government, academia, and clinicians.
  • Following the Respiratory Innovation Summit, Polarean will be exhibiting at the 2023 ATS International Conference, taking place 21-24 May.

Three Abstracts Focusing on the Clinical Utility of Veracyte’s Genomic Tests in ILD and Lung Cancer To Be Presented at ATS 2023 International Conference

Retrieved on: 
Monday, May 1, 2023
Research, Medical Devices, Medical Supplies, Infectious Diseases, Genetics, Clinical Trials, Biotechnology, Health, Science, Oncology, Abstract, Interstitial lung disease, ATS, Lung cancer, ILD, Clinical trial, American Thoracic Society, International Conference on Bioinformatics, Patient, Diagnosis, Conference, Medical imaging, Pulmonology, D.C

Veracyte, Inc. (Nasdaq: VCYT) today announced that three abstracts focused on the company’s genomic tests for interstitial lung disease (Envisia Genomic Classifier) and lung cancer (Percepta Nasal Swab) will be presented at the American Thoracic Society (ATS) 2023 International Conference.

Key Points: 
  • Veracyte, Inc. (Nasdaq: VCYT) today announced that three abstracts focused on the company’s genomic tests for interstitial lung disease (Envisia Genomic Classifier) and lung cancer (Percepta Nasal Swab) will be presented at the American Thoracic Society (ATS) 2023 International Conference.
  • The meeting will take place May 19-24 in Washington, D.C.
    “We look forward to these new data being shared at ATS 2023, which explore the impact of our Envisia Genomic Classifier on diagnosis and treatment decisions for patients with interstitial lung diseases, as well as in identifying patients whose ILD is likely to progress,” said Bill Bulman, M.D., Veracyte’s medical director for Pulmonology.
  • “In addition, expanded preliminary data will be presented regarding use of the Percepta Nasal Swab test on potentially cancerous lung nodules found on CT scans.”
    The following abstracts will be presented at the ATS 2023 International Conference:
    Title: Demonstrating Clinical Utility for a Nasal Genomic Classifier for Lung Nodules: Addressing the Clinical Trial Learning Curve With a Familiarization Phase

New Book Reveals Secrets for Doctors Looking to Grow Their Practice

Retrieved on: 
Tuesday, April 25, 2023
PALM, Famous, Executive, Surgeon, Interview, Marketing, Elective surgery, Ophthalmology, Lung cancer, Pulmonology, Cardiology, Neurology, Dentist, Publishing, Physician, Television, Radio, Oncology, Pediatrics, PBS, Dentistry, Kindle, Amazon

PALM DESERT, Calif., April 25, 2023 /PRNewswire/ -- The new book 7 Ways to Become a Famous Doctor written by Roland Perez, the Executive Producer of PBS's longest-running national series, The American Health Journal, is now available on Amazon in both Kindle and physical formats. The book is a culmination of Roland's over 30 years of television broadcasting experience, having conducted over 7500 interviews with physicians.

Key Points: 
  • The book is a culmination of Roland's over 30 years of television broadcasting experience, having conducted over 7500 interviews with physicians.
  • "The number of times I heard 'you should write a book' finally stuck and set out to create a comprehensive yet easy-to-read how-to guidebook for physicians looking to expand their practice."
  • The book comprises seven main chapters: television, radio, print, digital, publishing, public relations, and events.
  • It is written for most practicing doctors like cosmetic surgeons, cosmetic dermatologists, cosmetic dentists, implant dentists, orthopedics, cardiologists, pulmonologists, oncologists, pediatricians, lung cancer, neurologists, ophthalmologists, and more.

The Inner Circle Acknowledges, Gary L. Berg as a Most Trusted Healthcare Professional for his contributions to the field of Pulmonology

Retrieved on: 
Monday, April 24, 2023
Bachelor, DOS, Des Moines University, Osteopathic medicine in the United States, Internal medicine, Ascension Michigan, Public, AOBIM, Respiratory system, Attention, American Osteopathic Association, AOA, Inner circle, American Osteopathic Board of Internal Medicine, Organization, Public health, Physician, Michigan State University, Doctor of Osteopathic Medicine, Hospital, Patient, Sleep, Ascension, Disease, Nursing, Dentistry, Microbiology, Pulmonology

BLOOMFIELD HILLS, Mich., April 24, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Gary L. Berg is acknowledged as a Most Trusted Healthcare Professional for his contributions to the field of Pulmonology.

Key Points: 
  • BLOOMFIELD HILLS, Mich., April 24, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Gary L. Berg is acknowledged as a Most Trusted Healthcare Professional for his contributions to the field of Pulmonology.
  • He completed an internship and residency at Ascension Macomb-Oakland Hospital and is board-certified in pulmonary disease and internal medicine by the American Osteopathic Board of Internal Medicine (AOBIM).
  • According to Dr. Berg, pulmonology is a medical specialty that deals with diseases involving the respiratory tract.
  • The doctor has been married to Mrs. Carolyn Berg for 30 years and they have one daughter, Elizabeth.

ReCode Therapeutics Appoints John G. Matthews, MBBS, MRCP, Ph.D., as Senior Vice President, Clinical Development

Retrieved on: 
Monday, April 17, 2023
Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, 23andMe, GSK plc, Royal Brompton Hospital, Asthma, Drug development, MBBS, Therapy, SORT, Doctor of Philosophy, Bias, MBA, Recode, Inflammation, Messenger, Pulmonology, Novartis, Lane, Patient, Respiratory disease, Cystic fibrosis, Hospital, LNP, Biomarker, Pharmacology, Imperial College London, MRCP, Disease, Medical device, Pharmaceutical industry, Genentech

ReCode Therapeutics , a clinical-stage genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced today the appointment of John G. Matthews, MBBS, MRCP, Ph.D., as senior vice president of clinical development.

Key Points: 
  • ReCode Therapeutics , a clinical-stage genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced today the appointment of John G. Matthews, MBBS, MRCP, Ph.D., as senior vice president of clinical development.
  • Dr. Matthews will oversee clinical development planning and strategy.
  • “We are delighted to welcome Dr. Matthews to build and lead our clinical team,” said Shehnaaz Suliman, M.D., MBA, M.Phil., chief executive officer, ReCode Therapeutics.
  • He spent the previous ten years at Genentech, a subsidiary of Roche, in leadership roles including senior group medical director.

Evolution Research Group, LLC Further Expands Early Phase Capabilities at Clinical Pharmacology of Miami (CPMI) with Increased Medical Team Expertise

Retrieved on: 
Wednesday, April 12, 2023
Clinical pharmacology, Obesity, University, ERG, Diabetes, Internal medicine, SLT, Kidney disease, Public, Obstetrics and gynaecology, Clinical trial, NDA, DRS, Pharmacy, Liver, Pulmonology, Neuroscience, Pharmacist, Pain management, Medical director, MD, CPMI, Gynaecology, CSF, Growth, Principal, Safety, Organon, Pharmaceutical industry, Obstetrics, Anesthesiology, Bayer, Medicine

The expansion of the medical team has enabled CPMI to offer additional capabilities such as CSF sampling, which is currently in high demand.

Key Points: 
  • The expansion of the medical team has enabled CPMI to offer additional capabilities such as CSF sampling, which is currently in high demand.
  • Dr. Prezioso then accepted a role as Medical Director and Principal Investigator with a phase 1 unit in the northeast before relocating to Florida.
  • "I am thrilled to have joined the team at CPMI and am amazed by the growth they have experienced under the ownership of ERG.
  • Dr. Fernandez received his medical degree at the University of Miami, Miller School of Medicine, where he also did his residency training.